Loading…

Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity

The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity....

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021, Vol.12, p.599526
Main Authors: Binder, Christian, Sellberg, Felix, Cvetkovski, Filip, Berg, Stefan, Berglund, Erik, Berglund, David
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413
cites cdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413
container_end_page
container_issue
container_start_page 599526
container_title Frontiers in immunology
container_volume 12
creator Binder, Christian
Sellberg, Felix
Cvetkovski, Filip
Berg, Stefan
Berglund, Erik
Berglund, David
description The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2 monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.
doi_str_mv 10.3389/fimmu.2021.599526
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b681b0ce2a704f868ecdd8ecade323fd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b681b0ce2a704f868ecdd8ecade323fd</doaj_id><sourcerecordid>2494881356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</originalsourceid><addsrcrecordid>eNp1Uk1v1DAQjRCIVqU_gAvKkQNZ_B37grTa0rKiwIEVFw6WY092XZJ46yTA9tfj_WjpHurDeDR-783Yfln2GqMJpVK9r33bjhOCCJ5wpTgRz7JTLAQrKCHs-aP8JDvv-xuUFlOUUv4yO6FUMEqROs1-fvfrxt-NranyeedGC33-9XM-g6bJL6MZorfeQb5YxTAuV_m0G3wV3Ka4gDV0DrphBy2-gPNmAJfPNkMYwt_EGjavshe1aXo4P-xn2eLy42L2qbj-djWfTa8LyxUaClEbXjsEWCirOLJcls4yZ0snOBYEi5LXWBInMTKAjKFGMCwYoVCVJcP0LJvvZV0wN3odfWviRgfj9a4Q4lKbOHjbgK6ExBWyQEyJWC2FBOtcCsYBJbR2SavYa_V_YD1WR2qH0q-UgWaCKlYmvHoSv47B_SfdEzHjSnJGROK-e5J74X9Md5OPo2ZUSSIT_MMenrAtOJvePprmuOPRSedXehl-61Ihlq6aBN4eBGK4HaEfdOt7m37PdBDGXhOmmJSY8u1oeA-1MfR9hPqhDUZ66z69c5_euk_v3Zc4bx7P98C49xr9BzKy2d0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494881356</pqid></control><display><type>article</type><title>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</title><source>PubMed Central</source><creator>Binder, Christian ; Sellberg, Felix ; Cvetkovski, Filip ; Berg, Stefan ; Berglund, Erik ; Berglund, David</creator><creatorcontrib>Binder, Christian ; Sellberg, Felix ; Cvetkovski, Filip ; Berg, Stefan ; Berglund, Erik ; Berglund, David</creatorcontrib><description>The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2 monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2021.599526</identifier><identifier>PMID: 33643309</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Antibodies, Monoclonal, Humanized - pharmacology ; Antibody-Dependent Cell Cytotoxicity ; antibody-dependent cell-mediated cytotoxicity ; CD2 ; CD2 Antigens - antagonists &amp; inhibitors ; CD2 Antigens - immunology ; Humans ; Immunology ; Jurkat Cells ; Killer Cells, Natural - immunology ; Lymphocyte Activation - drug effects ; Lymphocyte Depletion ; Medicin och hälsovetenskap ; NK alloreactivity ; NK cell ; Receptors, IgG - immunology ; siplizumab ; spontaneous cytotoxicity</subject><ispartof>Frontiers in immunology, 2021, Vol.12, p.599526</ispartof><rights>Copyright © 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund.</rights><rights>Copyright © 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</citedby><cites>FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904868/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904868/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4023,27922,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33643309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-439828$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:145985426$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Binder, Christian</creatorcontrib><creatorcontrib>Sellberg, Felix</creatorcontrib><creatorcontrib>Cvetkovski, Filip</creatorcontrib><creatorcontrib>Berg, Stefan</creatorcontrib><creatorcontrib>Berglund, Erik</creatorcontrib><creatorcontrib>Berglund, David</creatorcontrib><title>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2 monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.</description><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Antibody-Dependent Cell Cytotoxicity</subject><subject>antibody-dependent cell-mediated cytotoxicity</subject><subject>CD2</subject><subject>CD2 Antigens - antagonists &amp; inhibitors</subject><subject>CD2 Antigens - immunology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Jurkat Cells</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocyte Depletion</subject><subject>Medicin och hälsovetenskap</subject><subject>NK alloreactivity</subject><subject>NK cell</subject><subject>Receptors, IgG - immunology</subject><subject>siplizumab</subject><subject>spontaneous cytotoxicity</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1Uk1v1DAQjRCIVqU_gAvKkQNZ_B37grTa0rKiwIEVFw6WY092XZJ46yTA9tfj_WjpHurDeDR-783Yfln2GqMJpVK9r33bjhOCCJ5wpTgRz7JTLAQrKCHs-aP8JDvv-xuUFlOUUv4yO6FUMEqROs1-fvfrxt-NranyeedGC33-9XM-g6bJL6MZorfeQb5YxTAuV_m0G3wV3Ka4gDV0DrphBy2-gPNmAJfPNkMYwt_EGjavshe1aXo4P-xn2eLy42L2qbj-djWfTa8LyxUaClEbXjsEWCirOLJcls4yZ0snOBYEi5LXWBInMTKAjKFGMCwYoVCVJcP0LJvvZV0wN3odfWviRgfj9a4Q4lKbOHjbgK6ExBWyQEyJWC2FBOtcCsYBJbR2SavYa_V_YD1WR2qH0q-UgWaCKlYmvHoSv47B_SfdEzHjSnJGROK-e5J74X9Md5OPo2ZUSSIT_MMenrAtOJvePprmuOPRSedXehl-61Ihlq6aBN4eBGK4HaEfdOt7m37PdBDGXhOmmJSY8u1oeA-1MfR9hPqhDUZ66z69c5_euk_v3Zc4bx7P98C49xr9BzKy2d0</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Binder, Christian</creator><creator>Sellberg, Felix</creator><creator>Cvetkovski, Filip</creator><creator>Berg, Stefan</creator><creator>Berglund, Erik</creator><creator>Berglund, David</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>2021</creationdate><title>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</title><author>Binder, Christian ; Sellberg, Felix ; Cvetkovski, Filip ; Berg, Stefan ; Berglund, Erik ; Berglund, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Antibody-Dependent Cell Cytotoxicity</topic><topic>antibody-dependent cell-mediated cytotoxicity</topic><topic>CD2</topic><topic>CD2 Antigens - antagonists &amp; inhibitors</topic><topic>CD2 Antigens - immunology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Jurkat Cells</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocyte Depletion</topic><topic>Medicin och hälsovetenskap</topic><topic>NK alloreactivity</topic><topic>NK cell</topic><topic>Receptors, IgG - immunology</topic><topic>siplizumab</topic><topic>spontaneous cytotoxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Binder, Christian</creatorcontrib><creatorcontrib>Sellberg, Felix</creatorcontrib><creatorcontrib>Cvetkovski, Filip</creatorcontrib><creatorcontrib>Berg, Stefan</creatorcontrib><creatorcontrib>Berglund, Erik</creatorcontrib><creatorcontrib>Berglund, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Binder, Christian</au><au>Sellberg, Felix</au><au>Cvetkovski, Filip</au><au>Berg, Stefan</au><au>Berglund, Erik</au><au>Berglund, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2021</date><risdate>2021</risdate><volume>12</volume><spage>599526</spage><pages>599526-</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2 monoclonal antibodies in the absence of Fc γ receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to FcγRIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33643309</pmid><doi>10.3389/fimmu.2021.599526</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2021, Vol.12, p.599526
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b681b0ce2a704f868ecdd8ecade323fd
source PubMed Central
subjects Antibodies, Monoclonal, Humanized - pharmacology
Antibody-Dependent Cell Cytotoxicity
antibody-dependent cell-mediated cytotoxicity
CD2
CD2 Antigens - antagonists & inhibitors
CD2 Antigens - immunology
Humans
Immunology
Jurkat Cells
Killer Cells, Natural - immunology
Lymphocyte Activation - drug effects
Lymphocyte Depletion
Medicin och hälsovetenskap
NK alloreactivity
NK cell
Receptors, IgG - immunology
siplizumab
spontaneous cytotoxicity
title Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A36%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Siplizumab%20Induces%20NK%20Cell%20Fratricide%20Through%20Antibody-Dependent%20Cell-Mediated%20Cytotoxicity&rft.jtitle=Frontiers%20in%20immunology&rft.au=Binder,%20Christian&rft.date=2021&rft.volume=12&rft.spage=599526&rft.pages=599526-&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2021.599526&rft_dat=%3Cproquest_doaj_%3E2494881356%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c590t-6fa5fd0e169c950c587dc4dc7d651621675f182d810ae0aa3a6416423eb77413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2494881356&rft_id=info:pmid/33643309&rfr_iscdi=true